Business

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

Financial Post · October 21, 2026 at 8:30 a.m.

Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials SAN DIEGO, Oct.

21, 2026 (GLOBE NEWSWIRE

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling

More from Financial Post

Hercules Metals Announces $30 Million ‘Bought Deal’ Private Placement of Common Shares

SHARC Energy Receives Record Purchase Order from City of Surrey for District Energy Sewer Heat Recovery Project

Orca Energy Group Announces Appeal of the Decision of the Fair Competition Commission of Tanzania Prohibiting the Proposed Transaction

News of the day: Macklem rolls the dice, losing faith in housing, credit rating help, Joly threatens steel lawsuit, small business exits and more

More in Business

Hercules Metals Announces $30 Million ‘Bought Deal’ Private Placement of Common Shares

SHARC Energy Receives Record Purchase Order from City of Surrey for District Energy Sewer Heat Recovery Project

Orca Energy Group Announces Appeal of the Decision of the Fair Competition Commission of Tanzania Prohibiting the Proposed Transaction

News of the day: Macklem rolls the dice, losing faith in housing, credit rating help, Joly threatens steel lawsuit, small business exits and more

Exchange Income Corporation Completes Acquisition of TerraPro

Belgravia Announces Effective Date of Share Consolidation